Redx excited about potential new MRSA breakthrough

Redx excited about potential new MRSA breakthrough

LIVERPOOL-based drug development company has announced it has discovered a potentially important new antibiotic to fight MRSA.

The AIM-listed company said it had reached pre-clinical development stage with a new anti-infective compound designed to tackle the MRSA bacterium that causes potentially lethal infections in humans.

A statement said: “The discovery is a significant milestone for Redx’s commercial partnership with the NHS, working with The Royal Liverpool and Broadgreen University Hospitals Trust. This is the third Redx program to identify a drug development candidate since the beginning of the year.”

See the article in full at TheBusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.